@dylangemelli I found retatrutide easier to handle for most of my clients.They are going in stages of efficacy and improvements, etc...
I sat in on a multitude of conferences at the A4M this year and some other biohacking conventions and have also had some pretty in depth discussions with some of the best naturopathic doctors in the world and have gotten a ton of insight on GLP-1 Agonists and in depth analysis and understanding of the main three, ozempic, mounjaro and now retatrutide...
in short, mounjaro (tirzepatide) has the added GIP receptor which makes it stronger than ozempic (semaglutide) but then retatrutide goes one step fruther and you get the following three...
- GIP (Gastric Inhibitory Polypeptide) receptor
- GLP-1 (Glucagon-Like Peptide-1) receptor
- GCG (Glucagon) receptor
Heres a recent 48 week trial that was done on people with obesity, or overweight with weight-related conditions—except type 2 diabetes.
Dosage 24-Week Results 48-Week Results 1 mg 7.2% 8.7% 4 mg 12.9% 16.3% 8 mg 17.3% 23.9% 12 mg 17.5% 24.2% Placebo 1.6% 2.1%
Retatutride vs Tirzepatide vs Semaglutide: A Comparison
Medication Weight Loss Duration Type of Receptor Agonist FDA-approval for Weight Loss Retatrutide 24.2% 48 weeks Triple Trials Ongoing Semaglutide 20% 68 weeks Single Yes, under Wegovy Tirzepatide 26.6% 84 weeks Dual Yes, under Zepbound
Here are some ACTUAL study data showing the downside that has been seen with it so far
In clinical trials, retatrutide has shown promising results for weight loss, but like any medication, it comes with potential side effects and considerations. Phase II trial results did include data on adverse events:
- A significant percentage of participants (73% to 94%) reported adverse events while taking retatrutide, particularly in the higher 8-mg and 12-mg groups.
- The most commonly experienced side effects were gastrointestinal issues, including nausea, diarrhea, vomiting, and constipation.
- Digestive side effects mainly occurred during the dose escalation phase and were mostly mild to moderate in severity—lower starting doses seemed to lessen this severity.
- There were slight increases in certain digestive enzyme levels, such as amylase and lipase. But there was only one reported serious case of pancreatitis.
- Participants taking higher doses of retatrutide experienced an increase in heart rate during the first 24 weeks, after which it decreased.
- No serious cases of low blood sugar or significant complications like thyroid cancer were reported among participants.
- Some individuals (7% of those on retatrutide compared to 1% on placebo) experienced skin sensitivity, but these cases were not serious.
There is a firm belief it will eventually get through trials and be on bigger than the others and with the amount of money in this market now, i would venture to guess that to be true.. i will be doing a TON more in terms of discussion and study on it along with all GLP-1's and have been developing a significant amount of knowledge base on them because there are some pretty insane comments and opinions out there amongst media, social media etc. that are just insanely off base and non factual so it can be difficult to sift through the bull shit but im on it!

The most sides I saw was from semaglutide, even with micro dosing it has sides, @Pigsy just did micro dosing log with semgalutide, it's up here
https://www.evolutionary.org/forums/threads/semaglutide-ozempic-log.102197/